A pilot study of high‐dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0–N3M0 squamous cell carcinoma of the upper aerodigestive tractSee related editorial on pages 447–50, this issue.

This Phase I clinical trial was developed to assess the feasibility of combining high‐dose intraarterial cisplatin chemotherapy with concurrent, concomitant boost accelerated radiation therapy for patients with previously untreated T4 and select patients with T3N0–N3M0 squamous cell carcinoma of the upper aerodigestive tract.Between July 1999, and February 2002, 19 patients were treated with 3 or 4 weekly cycles of intraarterial Cisplatin chemotherapy (150 mg/m2) with concurrent, concomitant boost accelerated radiation therapy (72 grays in 42 fractions over 6 weeks).Two patient deaths occurred among the first 15 patients enrolled. Both patients presented with febrile neutropenia, and both died of complications related to infection. The number of cycles of intraarterial cisplatin was reduced from four cycles to three cycles, and an additional four patients were treated. The fourth patient treated on the modified protocol developed febrile neutropenia, sepsis, and a thromboembolic event, which resulted in lower extremity amputations. The maximum acute toxicity experienced was Grade 2 in 6 patients, Grade 3 in 5 patients, Grade 4 in 6 patients, and Grade 5 in 2 patients. With a median follow‐up of 21 months (range, 6.2–34.6 months), the overall survival at 1 year was 89.5% (95% confidence interval [95%CI], 76.7–100%). At 1 year, 92.9% of the patients were free from disease progression (95%CI, 80.3–100%).The results of this study suggest that concurrent intraarterial cisplatin chemotherapy at a dose of 150 mg/m2 with concomitant boost accelerated radiation therapy is not feasible. Cancer 2005. © 2004 American Cancer Society.